| 翻訳と辞書 |
| ViroPharma Incorporated ： ウィキペディア英語版 |
ViroPharma
ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014.〔(Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug, 11-11-2013 )〕 ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.
The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008.〔(【引用サイトリンク】title=Lev Pharmaceuticals Investor Relations )〕
==History==
ViroPharma Incorporated was founded in 1994 by Claude H. Nash (Chief Executive Officer), Mark A. McKinlay (Vice President, Research & Development), Marc S. Collett (Vice President, Discovery Research), Johanna A. Griffin (Vice President, Business Development), and Guy D. Diana (Vice President, Chemistry Research.) None of the founders are still with the company.
In November 2014, Shire plc acquired ViroPharma for$4.2 billion.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「ViroPharma」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|